You are here

  • Home
  • Archive
  • Volume 76, Issue 3
  • Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs
Free

https://doi.org/10.1136/annrheumdis-2014-207178corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs. Ann Rheum Dis 2016;75:1293–1301. The second trial number has been corrected to NCT00550446

    Linked Articles